Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study†

Aims We examined the efficacy, safety and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in Japanese patients with type 2 diabetes (T2DM) undergoing diet and exercise therapy. Methods Patients aged 20–80 years with T2DM diagnosed ≥3 months previously, and HbA1c of 6.9–9....

Descripción completa

Detalles Bibliográficos
Autores principales: Inagaki, N, Kondo, K, Yoshinari, T, Maruyama, N, Susuta, Y, Kuki, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906835/
https://www.ncbi.nlm.nih.gov/pubmed/23782594
http://dx.doi.org/10.1111/dom.12149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906835/
https://www.ncbi.nlm.nih.gov/pubmed/23782594
http://dx.doi.org/10.1111/dom.12149

Ejemplares similares